JERUSALEM, April 29, 2013 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013. The poster will be presented today, April 29 th, by Dr. Miriam Kidron, Oramed's Chief Scientific Officer, between 5:00pm-7:00pm EDT during the poster session and evening reception in the Ballroom Foyer of the Hyatt Regency Hotel.
The work summarizes the results of Oramed's key clinical studies assessing the safety and efficacy of its oral insulin formulation (ORMD-0801) in patients with Type 1 diabetes (T1DM) and in a subpopulation of T1DM patients who experience frequent and unpredictable swings in their blood sugar levels. ORMD-0801 was safe and well tolerated and effectively kept blood sugar levels in check, when administered before meals. In addition, the blood sugar readings of unstable T1DM patients more frequently fell within the normal range, when compared to those of the pretreatment monitoring sessions. The presented results demonstrate that Oramed's technology effectively delivers insulin without compromising its bioactivity, and serve as an impetus to realize the therapeutic potential of ORMD-0801 in regulating T1DM.
The poster will be available on Oramed's website later this evening, following the poster presentation time, at: http://oramed.com/index.php?page=13About The Global Technology Community Diabetes Summit The GTC Diabetes Summit is the only diabetes conference that provides delegates the opportunity to facilitate discussions and collaborations among affiliations (industry, academia, government) that can lead to the advancement of therapeutics and development of drugs/treatments for diabetes, and hopefully one day a cure. In addition the conference will provide updated educational research on various novel targets, therapeutics, developments, and technologies; regulatory guidance; case studies on successful and/or unsuccessful clinical trials; and other relevant insights that can help delegates advance their own research and therapeutics.